



Immunoperoxidase and neutralization/RT-PCR to estimate the efficiency of the human rotavirus VP8 structural protein candidate subunit vaccine

Waled Morsy El-Senousy^{a*}, Abeer Shokeer^b, Usama M. Hegazy^b, Amr E. El-Hakim^b,
Seham F. Hasan^c

^aEnvironmental Virology Lab, Water Pollution Research Department, Environment and
Climate Change Research Institute, National Research Centre, Dokki, Giza, Egypt

^bMolecular Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza,
Egypt

^cBotany and Microbiology Department, Faculty of Science (Girls Branch), Al-Azhar University, Yossuf Abbas st.,
Nasr city, P.O. 11754, Cairo, Egypt



CrossMark

Abstract

Improving the efficiency of the methods to estimate the sensitivity and specificity of vaccines is of great need and value. Immunoperoxidase and neutralization/RT-PCR were accomplished to estimate the efficiency of the human rotavirus VP8 structural protein candidate subunit vaccine previously examined using a neutralization test in another study of our group. This neutralization test was performed for expressed proteins of common P genotypes (P8, P4, and P6) of human rotaviruses either separately or as a mix. In our present study, results showed that 1.4, 1.6, and 2 log₁₀ reduction of initial viral titre (10⁵ infectious viral units) were achieved with 1/32 dilution of the rabbit anti-sera which produced against the tested P8 protein using immunoperoxidase, neutralization followed by RT-PCR, and neutralization followed by nested RT-PCR respectively. Also, 0.9 log₁₀, 1.1 log₁₀, and 1.5 log₁₀ reductions of initial viral titre were achieved with 1/32 dilution of the rabbit anti-sera which produced against the tested P4 and P6 proteins using immunoperoxidase, neutralization followed by RT-PCR, and neutralization followed by nested RT-PCR respectively. The capacity of neutralization decreased with increasing the dilution of rabbit anti-sera. No significant difference was observed between the results of immunoperoxidase in relation to the neutralization test. Neutralization followed by RT-PCR for rotaviruses in MA104 cells infected with viruses showed higher sensitivity in the estimation of the human rotavirus Wa strain titre directly or after neutralization with antibodies of P8, P4, and P6 expressed proteins. Neutralization followed by nested RT-PCR may be recommended to estimate the efficiency of the human rotavirus VP8 candidate recombinant subunit vaccine.

Keywords: Human rotavirus, VP8, Recombinant subunit vaccine, Immunoperoxidase, Neutralization/RT-PCR

1. Introduction

Rotaviruses belong to the *Reoviridae* family and contain genomes consisting of eleven segments of dsRNA. The International Committee on Taxonomy of Viruses (ICTV) recognized eight species within the rotavirus genus: *Rotavirus* A, B, C, D, E, F, G, and H [1]. Viruses of the rotavirus group A (RVA) species had been the most widely studied, owing to their significance as the prime cause of severe diarrhea in infants and young children [2]. The World Health Organization (WHO) global rotavirus surveillance network estimated that the annual rotavirus-associated mortality is approximately 215,000 worldwide in children <5 years of age [3].

Rotavirus infections are widespread and by the age of five most children have had more than one rotavirus infection. Though children three months of age and younger, may not develop diarrhea symptoms when they are infected with rotavirus since they have transplacental maternal antibodies to protect them in the first few months of life [4]. The first infections are usually the most severe and take place when circulating maternal rotavirus-specific immunoglobulin G is declining. Recovery from a first rotavirus infection does not lead to permanent immunity, generally. Subsequent to several rotavirus infections, children develop natural antibodies that shield them from symptoms of diarrhea when they are reinfected. Consequent or recurrent rotavirus infections affect people of all ages and confer

*Corresponding author e-mail: waledmorsy@hotmail.com

Receive Date: 19 August 2023, Revise Date: 26 October 2023, Accept Date: 08 November 2023

DOI: [10.21608/EJCHEM.2023.230370.8457](https://doi.org/10.21608/EJCHEM.2023.230370.8457)

©2024 National Information and Documentation Center (NIDOC)

gradually more protection against severe disease [5-6].

Vaccination is considered the most effective public health strategy to prevent rotavirus disease and reduce the global burden of rotavirus gastroenteritis [7]. Vaccines take advantage of using relatively harmless foreign agents to evoke protective immunity for protection against several important pathogens. Vaccines can be divided according to route of administration into orally and parentally administered vaccines. Nowadays, many types of vaccines have been proposed and used in vaccine development such as live attenuated whole virus vaccines and non-living viral vaccines [8].

Although clinical trials of both RV1 (Rotarix®) and RV5 (RotaTeq®) vaccines demonstrated high efficacy (generally >85%) against severe rotavirus disease in high-income countries, trials performed in low-income countries of Asia and Africa have reported lower vaccine efficacy [9-12]. Clinical trials using RV5 conducted in Vietnam and Bangladesh demonstrated an efficacy of 51% [9]. Clinical trials using RV1 conducted in South Africa found the vaccine to be 40–64% effective [11].

Reasons for lower vaccine efficacy in developing settings are multifactorial. The presence of pre-existing maternal antibodies in the infant has been shown to neutralize vaccine antigen in the gut and also reduce the infant's immune response to vaccine antigen [13-15].

Recently, environmental enteropathy (EE) is recognized as an important factor in lowering oral vaccine efficacy in the developing world [16]. EE can be defined as chronic intestinal inflammation and dysfunction as a result of frequent intestinal infections. Villous blunting, chronic inflammation, and increased intestinal permeability are major characteristics of EE [17]. In developing countries, water and food are highly contaminated with a variety of microbes. Dweller Person from these regions has high oral intake of this type of contaminated food and water. This results in a high microbiota load in the intestine. It leads to chronic activation of the mucosal immune system and an altered intestinal immune system [18-19]. Under this circumstance, intestinal immune cells are constantly engaged in preventing infection by the microbiota. For this reason, the preoccupied cells show less affinity for oral vaccine antigens and thereby dampen immunity [20-21].

So, looking for safe and efficient vaccines is of great importance. Our group (Food-Borne Viruses Group) in the National Research Centre (Giza, Egypt) developed a recombinant subunit human rotavirus vaccine based on the common P types from Egyptian human rotavirus isolates (Seham F. Hasan et al., manuscript in preparation). The sensitivity of this

vaccine was examined using a neutralization assay. In this present work, our objective is to improve the efficiency of the methods used to determine the sensitivity of the examined vaccine using immunoperoxidase and neutralization followed by nested RT-PCR.

2. Materials and Methods

2.1. Human rotavirus Wa strain propagation

It was performed according to Arnold et al. [22]. Human rotavirus Wa strain (kindly provided by Prof. Dr. Javier Buesa, University of Valencia, Spain) was activated with trypsin to a final concentration of 10 µg/ml for 30 minutes. MA104 cell line of 80% confluent monolayer was used for viral propagation. Growth media was discarded and the cells were washed twice with serum-free media (Eagle's minimum essential medium). Activated human rotavirus Wa strain was inoculated on MA104 cell line and kept at 37 °C for 1 h to facilitate virus adsorption onto the cells. Following adsorption, virus inoculum was removed and washing the confluent monolayer once using serum-free media was performed. Serum-free maintenance medium containing trypsin (1 µg/ml) was added. Tissue culture flasks containing the monolayers which were incubated at 37°C were observed at 24 h intervals, under an inverted microscope for any alteration of cell morphology up to 4–5 days post infection. Thereafter, the plates were kept at -20 °C. For lysis of the rotavirus infected cells, 3 cycles of freezing-thawing were done. The inoculum obtained was clarified by centrifugation at 1,000 g for 15 min. The fluid containing the virus was aliquoted in small screw capped vials and stored at -20 C until further use.

2.2. Titration of human rotavirus Wa strain

Twelve multiwall plates with 80% confluent monolayer were selected for rotavirus infection. Ten-fold serial dilution for the activated human rotavirus Wa strain was performed as described above and virus and dilutions were inoculated separately on MA104 cell line and kept at 37 °C for 1 h to facilitate virus adsorption onto the cells. The inoculated cells were washed with serum-free media (Eagle's minimum essential medium). Serum-free maintenance medium containing trypsin (1 µg/ml) was added. Plates containing the monolayers were incubated at 37 °C and were observed at 24 h intervals, under an inverted microscope for any alteration of cell morphology up to 4–5 days post-infection to observe the cytopathogenic effect (CPE). Thereafter, the plates were kept at -20 C. For lysis of the rotavirus infected cells, 3 cycles of freezing-thawing were done. The inoculum obtained was clarified by centrifugation at 1,000 g for 15 min. The fluid containing the virus (if

present) was aliquoted in small screw capped vials and stored at -20 C until further use [22].

2.3. Neutralization/RT-PCR assay

This was performed according to Ruggeri and Greenberg [23], using 10^5 PFU of human rotavirus Wa strain kindly provided by Prof. Dr. Javier Buesa (University of Valencia, Spain) and with some modifications using Median Tissue Culture Infectious Dose (TCID₅₀) instead of plaque assay to calculate the reduction of viral titer using the antibodies of expressed proteins of three sequences of rotavirus VP8 partial gene fragment of the VP4 from the most frequent Egyptian human rotavirus P genotypes (P[8], P[4] and P[6]) of our previous study [24] with codon optimized. These produced antibodies previously performed (Seham F. Hasan et al., manuscript in preparation) were used separately and in combination with an equal serum volume of each genotype. Ten-fold dilutions, followed by bi-fold dilutions, were performed to examine the efficacy of the antibodies against the human rotavirus Wa strain. Each experiment was repeated three times. In the normal neutralization, only observation of CPE is usually performed and the last well containing CPE usually determines the titre of the virus either directly or neutralized with monoclonal or polyclonal antibodies. In our study, RT-PCR was performed for MA104 cells (after freezing, thawing, and centrifugation) of all wells previously inoculated with serial dilutions of the human rotavirus Wa strain, either directly or neutralized with antibodies produced in rabbits for the common P8, P4, and P6 genotypes of human rotavirus Egyptian isolates. Nested RT-PCR was performed. Results were estimated according to the neutralization index for the eight wells for direct virus (without dilution) and for each dilution [25].

2.4. Viral Nucleic Acid Extraction

Viral nucleic acid was extracted from 100 µl of the supernatant by BIOZOL Total RNA Extraction reagent (BioFlux, Japan) according to the manufacturer's instructions.

2.5. Nested RT PCR of a VP6 Coding Gene Fragment of Rotaviruses Group A

The primers used for RT-PCR to amplify a 379-bp region were the forward VP6-F 5'-GACGGVGCRACTACATGG T-3' and the reverse VP6-R 5'-GTCCAATTCATNCCTGGT GG-3' primers (1 µM of each) and according to Iturriza Gomara et al. [26] using 100 units of M-MLV reverse transcriptase enzyme (Thermo Fisher) in a total volume of 10 µl and 2.5 units of Taq DNA polymerase (Thermo Fisher) in a total volume of 50 µl. Nested PCR amplification of the target RT-PCR

products was performed using the forward VP6-NF 5'-GCWAGAAATTTTGATACA-3' and the reverse VP6-NR 5'-GATTCACAAACTGCAGA-3' primers 1 µM of each and according to Gallimore et al. [27] to amplify a 155 bp fragment. Ten µl of PCR products were analyzed by 3% agarose gels (Panreac-Spain). Nested RT-PCR was performed separately to the 8 wells for each dilution, which was examined for CPE using the neutralization test, and positivity was estimated using the neutralization index.

2.6. Indirect immunoperoxidase test (I-IPT)

Indirect IPT was performed as per the method described in the European Union diagnostic manual [28] with slight modification. MA104 cell monolayer that attaining approximately 80 % cell growth in 96 well tissue culture plate was infected with human rotavirus Wa strain as described above for 4-5 days. For fixation of cells, acetone/methanol (1:1) solution was added at a volume of 100 µl/well and left for 10 min at room temperature. The cell monolayer was treated with 0.4 % Triton X-100 (in PBS-T) for 5 min. The non-specific binding sites were blocked by 2 % BSA (in PBS-T) for 1 h at room temperature. Thereafter, 50 µl of polyclonal pig anti-rotavirus antibody (1:100 in 1 % BSA) was added to the wells. The plate was incubated for 1 h at 37 °C. After that, the plate was washed twice with PBS-T for 5 min. Then, rabbit anti-swine HRPO conjugate (DAKO, Denmark) diluted 1:1000 in 1 % BSA was added at the rate of 50 µl/well. The plate was incubated again at 37 °C for 1 h. After washing with PBS-T three times, the wells were filled with 50 µl of chromogen-substrate solution and stained for 15-30 min at room temperature. After discarding the substrate, the wells were washed with deionized water to stop the colour reaction. The plate was observed under an inverted microscope (Zeiss, Primo Vert, Germany) for evaluation of the results. Cells showing dark red staining of the cytoplasm were considered to be infected by rotavirus.

2.7. Statistics

Percentages of reduction and neutralization index were estimated for neutralization followed by RT-PCR and neutralization followed by nested RT-PCR. To compare the performance of used tests that were evaluated on the same antibodies originated from expressed proteins of P8, P4, and P6 partial genes inoculated in rabbits, the kappa test was used according to <http://epitools.ausvet.com.au/content.php?page=Compare2Tests> [29].

3. Results

3.1. Cytopathogenic effect (CPE) of human rotavirus Wa strain

A cytopathogenic effect was observed on MA104 cells after three days of infection with the human rotavirus Wa strain. The cytopathogenic effect was observed with different intensity according to the viral titre from virus without dilution till virus diluted to

10^{-3} . The shape of the cytopathogenic effect on the MA104 cell line infected with the human rotavirus Wa strain in relation to control cells is shown in Fig. 1 (A, B, and C).




Fig. 1. The shape of cytopathogenic effect on MA104 cell line infected with human rotavirus Wa strain in relation to control cells. A) Control MA104 cell line which was not infected with human rotavirus Wa strain after 3 days of incubation at 37°C. B) CPE on MA104 cell line infected with direct human rotavirus Wa strain without dilution after 3 days of incubation at 37°C. C) CPE on MA104 cell line infected with direct human rotavirus Wa strain diluted to 10^{-3} after 3 days of incubation at 37°C.

3.2. Sensitivity of immunoperoxidase and neutralization followed by RT-PCR for estimation of antibodies against expressed proteins P8, P4, and P6 human rotavirus genotypes

1.4, 1.6, and 2 \log_{10} reduction of initial viral titre (10^5 infectious viral units) were achieved with 1/32 dilution of the rabbit anti-sera which produced against the tested P8 protein using immunoperoxidase, neutralization followed by RT-PCR, and neutralization followed by nested RT-PCR respectively. The reduction was reduced with the dilution of the antisera which 1.1 \log_{10} , 1 \log_{10} , 0.7 \log_{10} , 0.5 \log_{10} , and 0.3 \log_{10} reductions were achieved with dilutions 1/100, 1/1000, 1/5000, 1/10000 and 1/15000 dilutions of the rabbit anti-sera using immunoperoxidase. Also, 1.3 \log_{10} , 1.2 \log_{10} , 0.8 \log_{10} , 0.7 \log_{10} , and 0.5 \log_{10} reductions were achieved with dilutions 1/100, 1/1000, 1/5000, 1/10000 and 1/15000 dilutions of the rabbit anti-sera using neutralization followed by RT-PCR. Using neutralization followed by nested RT-PCR, 1.6 \log_{10} , 1.5 \log_{10} , 1 \log_{10} , 0.8 \log_{10} , and 0.7 \log_{10} reductions were achieved with dilutions 1/100, 1/1000, 1/5000, 1/10000 and 1/15000 dilutions of the rabbit anti-sera. No reduction was observed for viral infectious units with a dilution of 1/20000 of the rabbit anti-sera using immunoperoxidase and neutralization followed by RT-PCR, while a 0.3 \log_{10} reduction was observed using neutralization followed by nested RT-PCR. No reduction was observed for all the methods used with a dilution of 1/25000 of the rabbit anti-sera of the expressed protein of human rotavirus P8 genotype. Also, 0.9 \log_{10} , 1.1 \log_{10} and 1.5 \log_{10} reductions of initial viral titre (10^5 infectious viral units) were achieved with 1/32 dilution of the rabbit anti-sera which produced against the tested P4 and P6 proteins using immunoperoxidase, neutralization followed by RT-PCR, and neutralization followed by nested RT-PCR respectively. The reduction was reduced with the dilution of the antisera which 0.6

\log_{10} , 0.6 \log_{10} , and 0.4 \log_{10} reductions were achieved with dilutions 1/100, 1/1000, and 1/5000 of the rabbit anti-sera for both P4 and P6 proteins using immunoperoxidase. Also, 0.9 \log_{10} , 0.8 \log_{10} , and 0.6 \log_{10} reductions were observed using neutralization followed by RT-PCR and 1.1 \log_{10} , 1.1 \log_{10} , and 0.9 \log_{10} were observed using neutralization followed by nested RT-PCR. No reduction was observed for viral infectious units with a dilution of 1/10000 of the rabbit anti-sera for P4 and P6 proteins using immunoperoxidase and neutralization followed by RT-PCR, while, 0.2 \log_{10} reduction was observed using neutralization followed by nested RT-PCR. No reduction was observed for viral infectious units at dilution 1/15000. Mixed P8, P4, and P6 antibodies achieved 1.1 \log_{10} reduction of initial viral titre (10^5 infectious viral units) with 1/32 of dilution of the rabbit anti-sera using immunoperoxidase.

Also, 0.9 \log_{10} , 0.8 \log_{10} , 0.6 \log_{10} , and 0.4 \log_{10} reductions were achieved with dilutions 1/100, 1/1000, 1/5000, and 1/10000 of the rabbit anti-sera respectively. Using neutralization followed by RT-PCR, 1.4 \log_{10} , 1.2 \log_{10} , 1 \log_{10} , 0.7 \log_{10} , and 0.5 \log_{10} were achieved with dilutions of 1/32, 1/100, 1/1000, 1/5000, and 1/10000 respectively, while using neutralization followed by nested RT-PCR, 1.7 \log_{10} , 1.5 \log_{10} , 1.3 \log_{10} , 1 \log_{10} , and 0.8 \log_{10} were achieved with dilutions 1/32, 1/100, 1/1000, 1/5000, and 1/10000 respectively. No reduction was observed for viral infectious units with dilution 1/15000 of the rabbit anti-sera using immunoperoxidase and neutralization followed by RT-PCR, while a 0.2 \log_{10} reduction was observed using neutralization followed by nested RT-PCR. No reduction was observed for viral infectious units at dilution 1/20000 (Fig. 2, 3, 4, and 5). Some wells with low CPE and other wells with no CPE observed on the MA104 cell line showed positive results using nested RT-PCR.




Fig. 2. Log₁₀ reduction of initial human rotavirus Wa strain titre using antibodies of expressed protein of P8 genotype.




Fig. 3. Log₁₀ reduction of initial human rotavirus Wa strain titre using antibodies of expressed protein of P4 genotype.




Fig. 4. Log₁₀ reduction of initial human rotavirus Wa strain titre using antibodies of expressed protein of P6 genotype.




Fig. 5. Log₁₀ reduction of initial human rotavirus Wa strain titre using antibodies of expressed protein of mixed P8, P4, and P6 genotypes.

4. Discussion

Sensitivity and specificity are usually the most important factors to estimate the quality of test methods [30]. On the other hand, the accuracy of test methods to estimate the efficiency of vaccines is of great concern [31]. In a previous work of our group (Seham F. Hasan et al., manuscript in preparation), a neutralization test was used to estimate the efficiency of antibodies produced in rabbits inoculated with expressed proteins of the most frequent isolates of the P8, P4, and P6 genotypes of human rotaviruses in Egypt to the neutralize infectious human rotavirus Wa strain. $1.5 \log_{10}$ reduction of initial viral titre (10^5 infectious viral units) were achieved with 1/32 dilution of the rabbit anti-sera which produced against the tested P8 protein. The reduction was reduced with the dilution of the antisera which $1.2 \log_{10}$, $1 \log_{10}$, $0.8 \log_{10}$, $0.6 \log_{10}$, and $0.3 \log_{10}$ reductions were achieved with dilutions 1/100, 1/1000, 1/5000, 1/10000 and 1/15000 of the rabbit anti-sera. No reduction was observed for viral infectious units with a dilution of 1/20000 of the rabbit anti-sera. Also, $0.9 \log_{10}$ reduction of initial viral titre (10^5 infectious viral units) was achieved with 1/32 dilution of the rabbit anti-sera which produced against the tested P4 and P6 proteins. The reduction was reduced with the dilution of the antisera which $0.7 \log_{10}$, $0.5 \log_{10}$, and $0.3 \log_{10}$ reductions were achieved with dilutions 1/100, 1/1000, and 1/5000 of the rabbit anti-sera for both P4 and P6 proteins. No reduction was observed for viral infectious units with dilution 1/10000 of the rabbit anti-sera for either P4 or P6 proteins respectively. Mixed P8, P4, and P6 antibodies achieved $1.2 \log_{10}$ reduction of the initial viral titre (10^5 infectious viral units) with 1/32 dilution of the rabbit anti-sera. Also, $1 \log_{10}$, $0.8 \log_{10}$, $0.5 \log_{10}$, and $0.3 \log_{10}$ reductions were achieved with dilutions 1/100, 1/1000, 1/5000, and 1/10000 of the rabbit anti-sera. No reduction was observed for viral infectious units with a dilution of 1/15000 of the rabbit anti-sera (Seham F. Hasan et al., manuscript in preparation). In our present study, different methods were used to compare their efficiencies in estimation of the potency of the antibodies to neutralize the human rotavirus Wa strain in relation to neutralization test. Our results indicated no significant difference in the efficiency of immunoperoxidase in relation to neutralization test for antibodies of all separate proteins of P8, P4, and P6 and also for P genotypes mix. Previous reports showed comparable sensitivity between immunoperoxidase and neutralization test in the detection of antibodies to chicken anaemia agent [32] and canine distemper virus [33]. Neutralization followed by RT-PCR or nested RT-PCR has significant higher efficiency in estimation of the capacity of antibodies to neutralize infectious virus. The values were higher in all dilutions examined. On

the other hand, neutralization followed by nested RT-PCR is more sensitive than neutralization followed by RT-PCR. A lot of previous reports were concerned with the higher sensitivity of nested RT-PCR than RT-PCR [34-37]. This may return to the higher number of amplification cycles to amplify a shorter fragment in the nested RT-PCR. The end point dilution at which neutralization could be happened was higher with neutralization followed by nested RT-PCR than the other used methods. Not only nested RT-PCR but also other confirmatory methods could be used to confirm the specificity and increase the sensitivity of the test such as southern blot hybridization. Villena and co-workers [38] reported higher positivity of rotaviruses using southern blot hybridization as a confirmatory method in relation to the positivity using only RT-PCR in environmental samples collected from Cairo and Barcelona.

On the other hand, using RT-PCR after neutralization may have some other advantages. The cytopathogenic effect of the human rotavirus Wa strain is sometimes slow, especially for the high dilutions of the virus, which means a low viral titre. So, sometimes it is difficult to determine the end point of viral titre either as viral titration or viral titre after neutralization with specific antibodies. Using the neutralization index to estimate the viral titre or efficiency of antibodies to neutralize the virus, some wells or dilutions could be neglected, however they contain infectious virus. RT-PCR and nested RT-PCR may be a suitable solution to confirm the positivity of these neglected wells or dilutions. In our present study, some wells had very low CPE or almost no observable CPE on MA104 cells, although, positivity with nested RT-PCR was observed. Previous reports showed the higher efficiency of CC-RT-PCR to accurately quantify the infectious units of fastidious viruses or slow CPE-causing viruses [39-43].

The nature of the test methods used is more or less similar; however, viral cell interaction happens either in immunoperoxidase or in neutralization. The difference is in the mechanism of detection of viral titre in these methods. Serological mechanism (enzyme reaction) of using conjugate and substrate for detection of antibody reacted with the antigen on some cell sites could happen in immunoperoxidase, however, observation of CPE and calculation of the end point of viral positivity are the mechanisms used in neutralization test. Using nested RT-PCR increases the efficiency of estimating the potency of antibodies to neutralize infectious viruses. RT-PCR confirms the positivity of the virus in some wells because of its action on viral genome amplification which succeeded to adsorb/penetrate the specific cell lines. Although using nested RT-PCR after a neutralization test is more expensive, its importance to accurately

estimate the efficiency of antibodies to neutralize infectious viruses and consequently the efficiency of the vaccine *in vitro* may force us to neglect the cost factor.

5. Conclusions

The efficiency of neutralization followed by nested RT-PCR to estimate the effectiveness of antibodies to neutralize infectious viruses is significantly higher than the efficiency of the immunoperoxidase or neutralization test. Neutralization followed by nested RT-PCR could be considered as a recommended method to estimate the efficiency of the recombinant subunit vaccine *in vitro*.

6. Conflicts of interest

All authors declare that there are no conflicts of interest.

7. Acknowledgments

This paper is based upon work supported by Science, Technology & Innovation Funding Authority (STDF) under Project ID: 26326, PI: Prof. Dr. Waled Morsy El-Senousy.

8. References

- [1] Attoui, H., Mertens, P.P.C., Becnel, J., Belaganahalli, S., Bergoin, M., Brussaard, C. P., Chappell, J.D., Ciarlet, M., Vas, M., Dermody, T.S., Dormitzer, F., Duncan, R., Fang, Q., Graham, R., Ogden, K., Harding, R.M., Hillman, B., Makkay, A., Marzachi, C., Zhou, H. (2012). Family Reoviridae. In: King, A.M.Q., Adams, M.J., Carstens, E.B., Lefkowitz, E.J., Editors. *Virus taxonomy: classification and nomenclature: ninth report of the International Committee on Taxonomy of Viruses*. 1st edition, Elsevier Academic Press, San Diego, California, USA, pp. 541–637. Doi: 10.1016/B978-0-12-384684-6.00051-3.
- [2] Greenberg, H.B., Estes, M. K. (2009). Rotaviruses: from pathogenesis to vaccination. *Gastroenterology*, 136: 1939–1951. doi: 10.1053/j.gastro.2009.02.076.
- [3] Tate, J.E., Burton, A.H., Boschi-Pinto, C., Steele, A.D., Duque, J., Parashar, U.D., the WHO-coordinated Global Rotavirus Surveillance Network. (2016). Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. *Clin. Infect. Dis.* 62: 96–105. doi: 10.1093/cid/civ1013.
- [4] Ray, P.G., Kelkar, S.D., Walimbe, A.M., Biniwale, V., Mehendale, S. (2007). Rotavirus immunoglobulin levels among Indian mothers of two socio-economic groups and occurrence of rotavirus infections among their infants up to six months. *J. Med. Virol.* 79: 341–349. doi: 10.1002/jmv.20804.
- [5] Cortese, M.M., Parashar, U.D., Centers for Disease Control and Prevention (CDC). (2009). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm. Rep.* 58: 1–25.
- [6] Esona, M. D., Gautam, R. (2015). Rotavirus. *Clin. Lab. Med.* 35: 363–391. doi: 10.1016/j.cll.2015.02.012.
- [7] WHO. (2009). Rotavirus vaccines: an update. *Wkly. Epidemiol. Rec.* 84: 533–540.
- [8] Nabil, A., Zyed, R., Javier, B., Mahjoub, A. (2012). Recombination and point mutations in type G rotavirus strains: the challenges of vaccine development. (In: Logie, C., Editor. Point mutation. 1st edition. *InTech, Croatia*, Chapter 6, pp. 133–158. doi: 10.5772/33629.
- [9] Zaman, K., Dang, D. A., Victor, J. C., Shin, S., Yunus, M., Dallas, M. J., Podder, G., Vu, D. T., Le TP, Luby, S. P., Le, H. T., Coia, M. L., Lewis, K., Rivers, S. B., Sack D. A., Schödel, F., Steele, A. D., Neuzil, K. M., Ciarlet, M. (2010). Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. *Lancet.* 376: 615–623. doi: 10.1016/S0140-6736(10)60889-6.
- [10] Breiman, R. F., Zaman, K., Armah, G., Sow, S. O., Anh, D. D., Victor, J. C., Hille, D., Ciarlet, M., Neuzil, K. M. (2012). Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. *Vaccine.* 30: 24–29. doi: 10.1016/j.vaccine.2011.08.124.
- [11] Groome, M.J., Page, N., Cortese, M.M., Moyes, J., Zar, H.J., Kapongo, C.N., Mulligan, C., Diedericks, R., Cohen, C., Fleming, J. A., Seheri, M., Mphahlele, J., Walaza, S., Kahn, K., Chhagan, M., Steele, A.D., Parashar, U.D., Zell, E.R., Madhi, S.A. (2014). Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. *Lancet Infect. Dis.* 14: 1096–1104. doi: 10.1016/S1473-3099(14)70940-5.
- [12] Aliabadi, N., Tate, J.E., Parashar, U.D. (2016). Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines. *Clin. Microbiol. Infect.* 22: 128–135. doi: 10.1016/j.cmi.2016.03.007.
- [13] Patel, M., Shane, A.L., Parashar, U.D., Jiang, B., Gentsch, J.R., Glass, R.I. (2009). Oral rotavirus vaccines: how well will they work

- where they are needed most? *J. Infect. Dis.* 200: 39–48. doi: 10.1086/605035.
- [14] Chan, J., Nirwati, H., Triasih, R., Bogdanovic-Sakran, N., Soenarto, Y., Hakimi, M., Duke, T., Buttery, J.P., Bines, J.P., Bishop, R.F., Kirkwood, C.D., Danchin, M.D. (2011). Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? *Vaccine*. 29: 1242–1247. doi: 10.1016/j.vaccine.2010.11.087.
- [15] Velasquez, D.E., Parashar, U., Jiang, B. (2018). Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors. *Expert. Rev. Vaccines*. 17: 145–161. doi: 10.1080/14760584.2018.1418665.
- [16] Valdez, Y., Brown, E.M., Finlay, B.B. (2014). Influence of the microbiota on vaccine effectiveness. *Trends Immunol.* 35: 526–537. doi: 10.1016/j.it.2014.07.003.
- [17] Korpe, P.S., Petri, W.A. (2012). Environmental enteropathy: critical implications of a poorly understood condition. *Trends Mol. Med.* 18: 328–336. doi: 10.1016/j.molmed.2012.04.007.
- [18] Jiang, B., Wang, Y., Saluzzo, J.F., Barger, K., Frchette, M.J., Glass, R.I. (2008). Immunogenicity of a thermally inactivated rotavirus vaccine in mice. *Hum. Vaccines*. 4: 143–147. doi: 10.4161/hv.4.2.5263.
- [19] Lopman, B.A., Pitzer, V.E., Sarkar, R., Gladstone, B., Patel, M., Glasser, J., Gambhir, M., Atchison, C., Grenfell, B.T., Edmunds, W.J., Kang, G., Parashar, U.D. (2012). Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. *PLoS One*. 7: e41720. doi: 10.1371/journal.pone.0041720.
- [20] Magwira, C.A., Taylor, M.B. (2018). Composition of gut microbiota and its influence on the immunogenicity of oral rotavirus vaccines. *Vaccine*. 36: 3427–3433. doi: 10.1016/j.vaccine.2018.04.091.
- [21] Mahmud-Al-Rafat, A., Muktedir, A., Muktedir, H., Karim, M., Maheshwari, A., Ahasan, M.M. (2018). Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden. *Infection*. 46: 15–24. doi: 10.1007/s15010-017-1082-4.
- [22] Arnold, M., Patton, J.T., McDonald, S.M. (2009) Culturing, storage, and quantification of rotaviruses. *Curr. Protoc. Microbiol.* Nov; Chapter 15:Unit 15C.3. doi: 10.1002/9780471729259.mc15c03s15.
- [23] Ruggeri, F.M., Greenberg, H.B. (1991). Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture. *J. Virol.* Vol. 65: 2211–2219.
- [24] El-Senousy, W.M., Abu Senna, A.S.M, Mohsen, N.A., Hasan, S.F., Sidkey, N.M. (2020). Clinical and environmental surveillance of rotavirus common genotypes showed high prevalence of common P genotypes in Egypt. *Food Environ. Virol.* 12: 99–117. doi: 10.1007/s12560-020-09426-0.
- [25] Corthier, G. (1976). Comparaison de deux méthodes in vitro de titrage des anticorps neutralisant le virus de la peste porcine classique [Comparison of 2 in vitro methods of titration of antibodies neutralizing the classic swine plague virus]. *Ann. Rech. Vet.* 7(4):349-60.
- [26] Iturriza Gómara, M., Wong, C., Blome, S., Desselberger, U., Gray, J. (2002). Molecular characterization of VP6 genes of human rotavirus isolates: correlation of genogroups with subgroups and evidence of independent segregation. *J. Virol.* 76(13): 6596–6601. doi: 10.1128/jvi.76.13.6596-6601.2002.
- [27] Gallimore, C.I., Taylor, C., Gennery, A.R., Cant, A.J., Galloway, A., Iturriza-Gómara, M., Gray, J.J. (2006). Environmental monitoring for gastroenteric viruses in a pediatric primary immunodeficiency unit. *J. Clin. Microbiol.* 44(2): 395–399. doi: 10.1128/JCM.44.2.395-399.2006.
- [28] Anon. European union diagnostic manual on swine fever (2002). Germany: Hanover, pp. 11–16.
- [29] <http://epitools.ausvet.com.au/content.php?page=Compare2Tests>.
- [30] Shreffler, J., Huecker, M.R. (2023). Diagnostic Testing accuracy: sensitivity, specificity, predictive values and likelihood ratios. [Updated 2023 Mar 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557491/>
- [31] Kennedy-Shaffer, L., Kahn, R., Lipsitch, M. (2021). Estimating vaccine efficacy against transmission via effect on viral load. *Epidemiology*. 32(6): 820–828. doi: 10.1097/EDE.0000000000001415.
- [32] Chettle, N.J., Eddy, R.K., Saunders, J., Wyeth, P.J. (1991). A comparison of serum neutralisation, immunofluorescence and immunoperoxidase tests for the detection of antibodies to chicken anaemia agent. *Vet. Rec.* 128(13): 304–6. doi: 10.1136/vr.128.13.304.
- [33] Soma, T., Ishii, H., Hara, M., Yamamoto, S., Yoshida, T., Kinoshita, T., Nomura, K. (2001). Comparison of immunoperoxidase plaque staining and neutralizing tests for canine distemper virus. *Vet. Res. Commun.* 25(4): 311–25. doi: 10.1023/a:1010682726245.

- [34] Fransen, K., Zhong, P., De Beenhouwer, H., Carpels, G., Peeters, M., Louwagie, J., Janssens, W., Piot, P., van der Groen, G. (1994). Design and evaluation of new, highly sensitive and specific primers for polymerase chain reaction detection of HIV-1 infected primary lymphocytes. *Mol. Cell Probes*. 8(4): 317–322. doi: 10.1006/mcpr.1994.1043.
- [35] Grace, M.B., Buzard, G.S., Hughes M.R., Gore-Langton R.E. (1998). Degradable dUMP outer primers in merged tandem (M/T)-nested PCR: low- and single-copy DNA target amplification. *Anal. Biochem.* Oct 1; 263(1):85-92. doi: 10.1006/abio.1998.2771. PMID: 9750148.
- [36] Mijatovic-Rustempasic, S., Esona, M.D., Williams, A.L., Bowen, M.D. (2016). Sensitive and specific nested PCR assay for detection of rotavirus A in samples with a low viral load. *J. Virol. Methods*. 236: 41–46. doi: 10.1016/j.jviromet.2016.07.007.
- [37] Green, M.R. Sambrook, J. (2019). Nested polymerase chain reaction (PCR). *Cold Spring Harb. Protoc.* 2019(2). doi: 10.1101/pdb.prot095182. PMID: 30710024.
- [38] Villena, C., El-Senousy, W. M., Abad, F. X., Pintó, R. M., Bosch, A. (2003). Group A rotavirus in sewage samples from Barcelona and Cairo: emergence of unusual genotypes. *Appl. Environ. Microbiol.* 69(7): 3919–3923. doi: 10.1128/AEM.69.7.3919-3923.
- [39] Reynolds, K.A., Gerba, C.P., Abbaszadegan, M., Pepper, L.L. (2001). ICC/PCR detection of enteroviruses and hepatitis A virus in environmental samples. *Can. J. Microbiol.* 47(2): 153-7.
- [40] Lee, S.H., Lee, C., Lee, K.W., Cho, H.B., Kim, S.J. (2005). The simultaneous detection of both enteroviruses and adenoviruses in environmental water samples including tap water with an integrated cell culture-multiplex-nested PCR procedure. *J. Appl. Microbiol.* 98(5):1020-9. doi: 10.1111/j.1365-2672.2004.02496.x.
- [41] El-Senousy, W.M., Guix, S., Abid, I., Pintó, R.M., Bosch, A. (2007). Removal of astrovirus from water and sewage treatment plants, evaluated by a competitive reverse transcription-PCR. *Appl. Environ. Microbiol.* 73(1): 164–167. doi: 10.1128/AEM.01748-06.
- [42] Shieh, Y.C., Wong, C.I., Krantz, J.A., Hsu, F.C. (2008). Detection of naturally occurring enteroviruses in waters using direct RT-PCR and integrated cell culture-RT-PCR. *J. Virol. Methods*. 149(1): 184–9. doi: 10.1016/j.jviromet.2007.12.013.
- [43] El-Senousy, W.M., Abou-Elela, S.I. (2017). Assessment and evaluation of an integrated hybrid anaerobic–aerobic sewage treatment system for the removal of enteric viruses. *Food Environ. Virol.* 9: 287–303. doi: 10.1007/s12560-017-9286-4.